Stephen Montgomery

8PUBLICATIONS
13CO-AUTHORS
Pharmaceutical delivery technologiesMolecular medicineRegenerative medicine (incl. stem cells)Geriatrics and gerontologyEconomic models and forecasting
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 08, 2025
Licensed Subcutaneous Infusion Therapies in Advanced Parkinson's Disease: An Indirect Treatment Comparison and Cost-Minimisation Analysis.

Marc Vérin, Ángel Sesar, Bharat Amlani

|Dec 22, 2022
To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis.

Stephen Maxwell Montgomery, Luke Green, Hajer Karoui

|May 16, 2022
Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.

S Montgomery, F Woodhouse, U Vudumula

|Mar 01, 2022
Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey.

Sophie Clare Laura Caseby, Fern Amy Woodhouse, Stephen Maxwell Montgomery

|Jun 21, 2018
When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.

Kathleen Mary Noon, Stephen Maxwell Montgomery, Nicholas Edward Adlard

|Jun 22, 2017
Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.

Stephen M Montgomery, Jeanette Kusel, Richard Nicholas

Pageof 2

Frequent Collaborators

2 joint publications

Fern Amy Woodhouse

2 joint publications

Martin Edward Duddy

1 joint publications

U Vudumula

1 joint publications

Amir Lass